The share of US adults currently taking GLP-1 medications for weight loss has climbed to 11% in 2026, up from 3% in 2024, according to a July 7 Gallup poll. The rise arrives just as CMS launched its Medicare GLP-1…
GLP-1s
Many telehealth platforms selling GLP-1s online prescribe the drugs without requiring a clinician to interact with the patient in real time, according to a secret shopper study conducted by researchers at Yale University School of Medicine and published July 6…
A cryptocurrency-fueled gray-market peptide market has surpassed a $100 million annual run rate as demand for lower-cost weight loss drugs continues to grow, according to a June 4 Chainalysis report. The report found that some Chinese chemical manufacturers that once…
An investigational oral GLP-1 receptor agonist helped adults with overweight or obesity lose up to 11.3% more body weight than placebo over 36 weeks, according to a phase 2b study published July 1 in Nature Medicine. Here are four things…
CMS is rolling out the Medicare GLP-1 Bridge program — a demonstration designed to give eligible Medicare Part D beneficiaries access to certain GLP-1s at a fixed monthly cost — July 1. CMS officials, including CMS Administrator Mehmet Oz, MD,…
Advertisement
The FDA has released the names of panel members who will weigh in on whether seven popular peptides should be more widely available for pharmacy compounding. The new roster mainly includes physicians who run wellness, longevity and regenerative medicine clinics…
Treatment with the GLP-1 receptor agonist semaglutide was associated with slower biological aging in adults with HIV-associated lipohypertrophy, according to a study published May 19 in Nature Communications. Here are four things to know:
GLP-1 receptor agonist use was associated with a higher risk of smell and taste disturbances among adults with Type 2 diabetes, according to a study published June 25 in JAMA Otolaryngology-Head & Neck Surgery. Here are four things to know…
The Institute for Safe Medication Practices has identified five recurring medication errors involving GLP-1 therapies as use of the medications continues to grow for diabetes and obesity treatment, according to a June 25 news release. The findings come as GLP-1…
Walgreens will begin supporting eligible Medicare beneficiaries through the new Medicare GLP-1 Bridge program at about 8,000 pharmacies when the initiative launches July 1. More than 56 million patients in the Medicare network may be eligible for the program, according…